Published in Immunity on October 16, 2009
T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med (2011) 12.58
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer (2011) 6.44
Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst (2010) 5.23
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood (2013) 2.91
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res (2011) 2.44
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Cancer immunotherapy--revisited. Nat Rev Drug Discov (2011) 2.26
Response definition criteria for ELISPOT assays revisited. Cancer Immunol Immunother (2010) 2.20
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med (2015) 1.92
Therapeutic cancer vaccines: are we there yet? Immunol Rev (2011) 1.86
Isolation and preservation of peripheral blood mononuclear cells for analysis of islet antigen-reactive T cell responses: position statement of the T-Cell Workshop Committee of the Immunology of Diabetes Society. Clin Exp Immunol (2010) 1.82
A model for harmonizing flow cytometry in clinical trials. Nat Immunol (2010) 1.70
A methodological framework to enhance the clinical success of cancer immunotherapy. Nat Biotechnol (2011) 1.38
Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond. Cancer Immunol Immunother (2010) 1.36
Meeting Report from the Second "Minimum Information for Biological and Biomedical Investigations" (MIBBI) workshop. Stand Genomic Sci (2010) 1.35
Interrogating the repertoire: broadening the scope of peptide-MHC multimer analysis. Nat Rev Immunol (2011) 1.32
Equivalence of ELISpot assays demonstrated between major HIV network laboratories. PLoS One (2010) 1.30
Surrogate end points in the design of immunotherapy trials: emerging lessons from type 1 diabetes. Nat Rev Immunol (2010) 1.22
Serum is not required for ex vivo IFN-gamma ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program. Cancer Immunol Immunother (2010) 1.21
Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology (2012) 1.17
Cancer vaccines. BMJ (2015) 1.07
Harmonization of the intracellular cytokine staining assay. Cancer Immunol Immunother (2012) 1.05
DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling time. Cancer Immunol Immunother (2012) 1.02
Systems biological approaches to measure and understand vaccine immunity in humans. Semin Immunol (2013) 0.98
Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols. Cancer Immunol Immunother (2012) 0.98
The immuno-oncology framework: Enabling a new era of cancer therapy. Oncoimmunology (2012) 0.97
An integrative paradigm to impart quality to correlative science. J Transl Med (2010) 0.93
Development and application of 'phosphoflow' as a tool for immunomonitoring. Expert Rev Vaccines (2010) 0.93
Biomarkers in T cell therapy clinical trials. J Transl Med (2011) 0.92
Overnight resting of PBMC changes functional signatures of antigen specific T- cell responses: impact for immune monitoring within clinical trials. PLoS One (2013) 0.90
A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocols. J Transl Med (2011) 0.90
Dendritic cells: are they clinically relevant? Cancer J (2010) 0.90
Abacavir-reactive memory T cells are present in drug naïve individuals. PLoS One (2015) 0.90
ELISPOTs Produced by CD8 and CD4 Cells Follow Log Normal Size Distribution Permitting Objective Counting. Cells (2015) 0.88
Evaluation of current cancer immunotherapy: hemato-oncology. Cancer J (2011) 0.88
New approaches to design HIV-1 T-cell vaccines. Curr Opin HIV AIDS (2010) 0.88
The simultaneous ex vivo detection of low-frequency antigen-specific CD4+ and CD8+ T-cell responses using overlapping peptide pools. Cancer Immunol Immunother (2012) 0.88
Effect of cryopreservation of peripheral blood mononuclear cells (PBMCs) on the variability of an antigen-specific memory B cell ELISpot. Hum Vaccin Immunother (2014) 0.86
The development of standard samples with a defined number of antigen-specific T cells to harmonize T cell assays: a proof-of-principle study. Cancer Immunol Immunother (2012) 0.86
Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8(+) T cells with detection by ELISPOT and HLA-multimer staining. Cancer Immunol Immunother (2014) 0.85
High Reproducibility of ELISPOT Counts from Nine Different Laboratories. Cells (2015) 0.83
Human papillomavirus 16 E2-, E6- and E7-specific T-cell responses in children and their mothers who developed incident cervical intraepithelial neoplasia during a 14-year follow-up of the Finnish Family HPV cohort. J Transl Med (2014) 0.82
The Stanford Data Miner: a novel approach for integrating and exploring heterogeneous immunological data. J Transl Med (2012) 0.82
Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study. Cancer Immunol Immunother (2015) 0.81
Immune cell profiling to guide therapeutic decisions in rheumatic diseases. Nat Rev Rheumatol (2015) 0.81
Immune monitoring in cancer vaccine clinical trials: critical issues of functional flow cytometry-based assays. Biomed Res Int (2013) 0.80
Managing Multi-center Flow Cytometry Data for Immune Monitoring. Cancer Inform (2015) 0.80
Evaluation of tumor response to cytokine-induced killer cells therapy in malignant solid tumors. J Transl Med (2014) 0.80
Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines. PLoS One (2016) 0.79
2015 Guidance on cancer immunotherapy development in early-phase clinical studies. Cancer Sci (2015) 0.79
Immunomonitoring in glioma immunotherapy: current status and future perspectives. J Neurooncol (2015) 0.79
Distinguishing Latent from Active Mycobacterium tuberculosis Infection Using Elispot Assays: Looking Beyond Interferon-gamma. Cells (2012) 0.79
Design of therapeutic vaccines: hepatitis B as an example. Microb Biotechnol (2011) 0.79
New concepts for building vocabulary for cell image ontologies. BMC Bioinformatics (2011) 0.79
Immunological Monitoring to Rationally Guide AAV Gene Therapy. Front Immunol (2013) 0.79
Minimum information about tolerogenic antigen-presenting cells (MITAP): a first step towards reproducibility and standardisation of cellular therapies. PeerJ (2016) 0.79
Dendritic cell subsets as vectors and targets for improved cancer therapy. Curr Top Microbiol Immunol (2011) 0.79
Rational design of HIV vaccine and microbicides: report of the EUROPRISE annual conference. J Transl Med (2010) 0.78
A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer. Oncotarget (2015) 0.78
First Proposal of Minimum Information About a Cellular Assay for Regenerative Medicine. Stem Cells Transl Med (2016) 0.77
Structured reporting of T cell assay results. Cancer Immun (2013) 0.77
Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial. Oncoimmunology (2015) 0.77
Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes. Clin Cancer Res (2016) 0.76
Advancing the field of cancer immunotherapy: MIATA consensus guidelines become available to improve data reporting and interpretation for T-cell immune monitoring. Oncoimmunology (2012) 0.76
Quality control, analysis and secure sharing of Luminex® immunoassay data using the open source LabKey Server platform. BMC Bioinformatics (2013) 0.75
Validation of an IFNγ/IL2 FluoroSpot assay for clinical trial monitoring. J Transl Med (2016) 0.75
Human papillomavirus 16-specific cell-mediated immunity in children born to mothers with incident cervical intraepithelial neoplasia (CIN) and to those constantly HPV negative. J Transl Med (2015) 0.75
Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients. JCI Insight (2017) 0.75
Detection and Tracking of NY-ESO-1-Specific CD8+ T Cells by High-Throughput T Cell Receptor β (TCRB) Gene Rearrangements Sequencing in a Peptide-Vaccinated Patient. PLoS One (2015) 0.75
Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination. J Immunol Res (2015) 0.75
Pushing the frontiers of T-cell vaccines: accurate measurement of human T-cell responses. Expert Rev Vaccines (2012) 0.75
The presence of human papillomavirus (HPV) in placenta and/or cord blood might result in Th2 polarization. Eur J Clin Microbiol Infect Dis (2017) 0.75
Emerging immunotherapies for rheumatoid arthritis. Hum Vaccin Immunother (2014) 0.75
One-stop shop for microarray data. Nature (2000) 13.54
Promoting coherent minimum reporting guidelines for biological and biomedical investigations: the MIBBI project. Nat Biotechnol (2008) 12.96
A prescription for human immunology. Immunity (2008) 4.09
HIV vaccine research: the way forward. Science (2008) 3.86
A clinical development paradigm for cancer vaccines and related biologics. J Immunother (2007) 2.97
Design of effective immunotherapy for human autoimmunity. Nature (2005) 2.48
A chromatic explosion: the development and future of multiparameter flow cytometry. Immunology (2008) 2.17
Toward the harmonization of immune monitoring in clinical trials: quo vadis? Cancer Immunol Immunother (2007) 2.00
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med (2011) 18.99
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
The Pathway Tools software. Bioinformatics (2002) 14.89
Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol (2002) 14.75
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A (2005) 10.89
Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer (2005) 9.46
The immunobiology of cancer immunosurveillance and immunoediting. Immunity (2004) 9.39
miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell (2007) 9.08
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol (2009) 8.68
The three Es of cancer immunoediting. Annu Rev Immunol (2004) 8.20
Adaptive immunity maintains occult cancer in an equilibrium state. Nature (2007) 8.14
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature (2012) 7.76
Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med (2014) 7.64
TLR3 deficiency in patients with herpes simplex encephalitis. Science (2007) 5.86
Flexible nets. The roles of intrinsic disorder in protein interaction networks. FEBS J (2005) 5.36
Cytometry by time-of-flight shows combinatorial cytokine expression and virus-specific cell niches within a continuum of CD8+ T cell phenotypes. Immunity (2012) 5.26
Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst (2010) 5.23
Direct observation of ligand recognition by T cells. Nature (2002) 5.21
Antibody therapy of cancer. Nat Rev Cancer (2012) 5.17
The cancer/testis genes: review, standardization, and commentary. Cancer Immun (2004) 4.78
Cell type-specific gene expression differences in complex tissues. Nat Methods (2010) 4.75
Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev (2002) 4.63
A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods (2002) 4.48
Exploiting the mutanome for tumor vaccination. Cancer Res (2012) 4.45
Role of LAG-3 in regulatory T cells. Immunity (2004) 4.36
TCR and Lat are expressed on separate protein islands on T cell membranes and concatenate during activation. Nat Immunol (2009) 4.22
Thymic selection determines gammadelta T cell effector fate: antigen-naive cells make interleukin-17 and antigen-experienced cells make interferon gamma. Immunity (2008) 4.21
Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity (2011) 3.97
Continuous T cell receptor signaling required for synapse maintenance and full effector potential. Nat Immunol (2003) 3.88
T cell killing does not require the formation of a stable mature immunological synapse. Nat Immunol (2004) 3.85
Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol (2008) 3.82
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A (2008) 3.80
Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant (2010) 3.79
Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. Immunity (2013) 3.72
Plasma membrane-associated proteins are clustered into islands attached to the cytoskeleton. Proc Natl Acad Sci U S A (2006) 3.60
Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res (2004) 3.59
Agonist/endogenous peptide-MHC heterodimers drive T cell activation and sensitivity. Nature (2005) 3.55
RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med (2010) 3.53
Genetic and environmental determinants of human NK cell diversity revealed by mass cytometry. Sci Transl Med (2013) 3.41
TCR-peptide-MHC interactions in situ show accelerated kinetics and increased affinity. Nature (2010) 3.40
T-cell-antigen recognition and the immunological synapse. Nat Rev Immunol (2003) 3.38
Virus-specific CD4(+) memory-phenotype T cells are abundant in unexposed adults. Immunity (2013) 3.38
Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med (2012) 3.29
Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients. J Clin Invest (2011) 3.28
The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev (2002) 3.28
Costimulation and endogenous MHC ligands contribute to T cell recognition. Nat Immunol (2001) 3.24
CD4 enhances T cell sensitivity to antigen by coordinating Lck accumulation at the immunological synapse. Nat Immunol (2004) 3.21
Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. Proc Natl Acad Sci U S A (2009) 3.19
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother (2007) 3.16
Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A (2010) 3.12
Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest (2005) 3.11
T cells use two directionally distinct pathways for cytokine secretion. Nat Immunol (2006) 3.01
Tumour immunity: effector response to tumour and role of the microenvironment. Lancet (2008) 2.94
Coupled folding and binding with alpha-helix-forming molecular recognition elements. Biochemistry (2005) 2.94
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood (2013) 2.91
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A (2011) 2.90
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
How T cells 'see' antigen. Nat Immunol (2005) 2.87
Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol (2007) 2.83
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci U S A (2004) 2.80
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest (2013) 2.77
A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res (2003) 2.73
Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res (2005) 2.73
The unfoldomics decade: an update on intrinsically disordered proteins. BMC Genomics (2008) 2.72
Lineage structure of the human antibody repertoire in response to influenza vaccination. Sci Transl Med (2013) 2.71
p63 expression profiles in human normal and tumor tissues. Clin Cancer Res (2002) 2.68
Genome-wide analysis of cancer/testis gene expression. Proc Natl Acad Sci U S A (2008) 2.66
Evidence that structural rearrangements and/or flexibility during TCR binding can contribute to T cell activation. Mol Cell (2003) 2.61
Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci U S A (2007) 2.61
Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood (2005) 2.60
NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res (2003) 2.53
Retracted CD4+ T cell autoimmunity to hypocretin/orexin and cross-reactivity to a 2009 H1N1 influenza A epitope in narcolepsy. Sci Transl Med (2013) 2.51
Analysis of the prognostic significance of microscopic margins in 2,084 localized primary adult soft tissue sarcomas. Ann Surg (2002) 2.47
Two-step binding mechanism for T-cell receptor recognition of peptide MHC. Nature (2002) 2.45
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res (2011) 2.44
NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res (2006) 2.44
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood (2013) 2.39
An endogenous positively selecting peptide enhances mature T cell responses and becomes an autoantigen in the absence of microRNA miR-181a. Nat Immunol (2009) 2.38
Short-term immunosuppression promotes engraftment of embryonic and induced pluripotent stem cells. Cell Stem Cell (2011) 2.35
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Immunosuppressive therapy mitigates immunological rejection of human embryonic stem cell xenografts. Proc Natl Acad Sci U S A (2008) 2.25
The zinc finger transcriptional repressor Blimp1/Prdm1 is dispensable for early axis formation but is required for specification of primordial germ cells in the mouse. Development (2005) 2.23
Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer. Proc Natl Acad Sci U S A (2008) 2.20
A single class II myosin modulates T cell motility and stopping, but not synapse formation. Nat Immunol (2004) 2.20
Response definition criteria for ELISPOT assays revisited. Cancer Immunol Immunother (2010) 2.20
Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci U S A (2007) 2.19